Le Lézard
Classified in: Health

Harrington Discovery Institute Announces 2024 Scholar-Innovator Award Recipients


10 physician-scientists have been selected for drug development grant to advance discoveries into the clinic

CLEVELAND, April 16, 2024 /PRNewswire/ -- Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2024 class of Harrington Scholar-Innovators. The scholar awards will support breakthrough new treatments for heart disease, autoimmune disorders, cancer, infectious disease, inflammation, and rare diseases using small molecule, nucleic acid, vaccine, biologic, and gene therapies.

Harrington Discovery Institute was established in 2012 to accelerate the development of new treatments to address major unmet needs in medicine and society. Since its founding, Harrington has supported 188 drugs-in-the-making, 66 institutions, 39 company launches, 21 clinical candidates, and 15 licenses to pharma.

"Harrington Scholar-Innovators are accomplished physician-scientists whose research demonstrates innovation, creativity and the potential for clinical impact. In surrounding each scholar with an experienced pharma and business development team, we are maximizing the therapeutic potential of great science," said Jonathan S. Stamler, MD, President, Harrington Discovery Institute, Distinguished University Professor and Robert S. and Sylvia K. Reitman Family Foundation Professor of Cardiovascular Innovation at University Hospitals and Case Western Reserve University.

"This extraordinary group of physician-scientists constitutes Harrington's twelfth class of Scholar-Innovators. We are excited to help them advance their discoveries towards patients in need," said Seth Field, MD, PhD, Director, Physician-Scientist Programs and Investigator, Harrington Discovery Institute and Becky Hennessy Endowed Master Clinician in Breast Cancer Genomics.

In addition to grant funding, Harrington provides guidance and oversight in drug and business development. Harrington Scholar-Innovators also have the opportunity to compete for acceleration funds up to $300,000 and to qualify for mission-related investment funds typically up to $2MM. Scholars have facilitated access to Harrington's mission-aligned commercial entities including the Advent-Harrington Impact Fund, and to its charitable partner Morgan Stanley GIFT Cures.

The 2024 Harrington Scholar-Innovator Award recipients, their organizations and fields of research are:  

Demetrios Braddock, MD, PhD ? Yale University
DNA-Degrading Enzyme for the Treatment of Lupus

Christopher Holley, MD, PhD ? Duke University 
Non-Coding RNA to Treat Atherosclerosis

Andrew Hsieh, MD ? Fred Hutchinson Cancer Research Center 
Targeting mRNA Translation in Cancer

Deepak Nijhawan, MD, PhD ? University of Texas Southwestern Medical Center  
Oral Treatment of Glioblastoma

Russell Pachynski, MD ? Washington University in St. Louis 
Tumor-Targeted Therapeutic that Recruits Immune Cells

David Raleigh, MD, PhD ? University of California, San Francisco  
An Antibody Inhibiting NOTCH3+ Stem Cells in Meningioma

Julie Saba, MD, PhD ? University of California, San Francisco
Gene Therapy for Sphingosine-1-Phosphate Lyase Insufficiency Syndrome (SPLIS) 

Carlos Subauste, MD ? Case Western Reserve University  
Small Molecule Inhibitors of CD40 for the Treatment of Inflammatory Disorders

Jordan Winter, MD ? University Hospitals Cleveland Medical Center 
Targeting Wild-Type IDH1 in Pancreatic Cancer 

Juliane Bubeck Wardenburg, MD, PhD ? Washington University in St. Louis  
Staphylococcus Aureus Vaccine to Provide Infant Protection 

Harrington Discovery Institute is now accepting Letters of Intent for the 2025 Harrington Scholar-Innovator Award. The deadline to submit a brief Letter of Intent is June 5, 2024 11:59 PM. The full application deadline, for those invited to submit, is August 7, 2024. Learn more and apply to the 2025 Scholar-Innovator Award at HarringtonDiscovery.org/Scholar-Innovators.

SOURCE Harrington Discovery Institute


These press releases may also interest you

at 17:21
On Tuesday, May 28, the Second Gentleman will deliver remarks at an event to raise awareness about the physical and mental health challenges affecting young people. The Second Gentleman will uplift the Biden-Harris Administration's actions to tackle...

at 17:05
Agenus Inc. ("Agenus") , a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted inducement awards to Eric Olson, in connection...

at 16:46
Vanda Pharmaceuticals Inc. (Vanda) today announced that the Company's Board of Directors (the "Board") carefully reviewed the revised unsolicited proposal from Future Pak, LLC ("FP") to acquire the Company for $7.25 to $7.75 per share in cash plus...

at 16:45
Nutex Health Inc. ("Nutex Health" or the "Company") , a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in nine states and primary care-centric, risk-bearing physician networks,...

at 16:40
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of...

at 16:30
Rakovina Therapeutics Inc. ("Rakovina" or the "Company") announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company dated May 29, 2023 (the "Indenture"), certain holders (each, a...



News published on and distributed by: